VYNE reports positive Phase 1b data for FMX114 in atopic dermatitis; appoints Baker Tilly as auditor after PwC dismissal

VYNE Therapeutics Inc.

FMX114 showed statistically significant reduction in ADSI score at week 2: -81.4% mean reduction vs -54.3% for vehicle (p=0.004).
Pruritus reduced 96.4% mean from baseline for FMX114 vs 45.8% for vehicle at week 2.
Phase 2a safety and efficacy results expected in Q2 2022.
Audit committee dismissed PwC as auditor effective April 6, 2022; appointed Baker Tilly US, LLP as new auditor.
PwC's 2021 report included going concern explanatory paragraph due to incurred losses and negative cash flows.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.